皮皮学,免费搜题
登录
logo - 刷刷题
搜题
【简答题】
Section A暂缺 Section B – ALL THREE questions are compulsory and MUST be attempted On 1 October 2015, Zanda Co acquired 60% of Medda Co’s equity shares by means of a share exchange of one new share in Zanda Co for every two acquired shares in Medda Co. In addition, Zanda Co will pay a further $0·54 per acquired share on 30 September 2016. Zanda Co has not recorded any of the purchase consideration and its cost of capital is 8% per annum. The market value of Zanda Co’s shares at 1 October 2015 was $3·00 each. The summarised statements of financial position of the two companies as at 31 March 2016 are: The following information is relevant: (i) At the date of acquisition, Zanda Co conducted a fair value exercise on Medda Co’s net assets which were equal to their carrying amounts (including Medda Co’s financial asset equity investments) with the exception of an item of plant which had a fair value of $2·5 million below its carrying amount. The plant had a remaining useful life of 30 months at 1 October 2015. The directors of Zanda Co are of the opinion that an unrecorded deferred tax asset of $1·2 million at 1 October 2015, relating to Medda Co’s losses, can be relieved in the near future as a result of the acquisition. At 31 March 2016, the directors’ opinion has not changed, nor has the value of the deferred tax asset. (ii) Zanda Co’s policy is to value the non-controlling interest at fair value at the date of acquisition. For this purpose, a share price for Medda Co of $1·50 each is representative of the fair value of the shares held by the noncontrolling interest. (iii) At 31 March 2016, Medda Co held goods in inventory which had been supplied by Zanda Co at a mark-up on cost of 35%. These goods had cost Medda Co $2·43 million. (iv) The financial asset equity investments of Zanda Co and Medda Co are carried at their fair values at 1 April 2015. At 31 March 2016, these had fair values of $6·1 million and $1·8 million respectively, with the change in Medda Co’s investments all occurring since the acquisition on 1 October 2015. (v) There is no impairment to goodwill at 31 March 2016. Required: Prepare the following extracts from the consolidated statement of financial position of Zanda Co as at 31 March 2016: (i) Goodwill; (ii) Retained earnings; (iii) Non-controlling interest. The following mark allocation is provided as guidance for this question: (i) 6 marks (ii) 7 marks (iii) 2 marks
手机使用
分享
复制链接
新浪微博
分享QQ
微信扫一扫
微信内点击右上角“…”即可分享
反馈
参考答案:
举一反三
【单选题】关于慢性支气管炎体征特点的描述,下列哪项错误
A.
早期可无任何异常体征
B.
急性发作期可有散在干湿罗音
C.
并发肺气肿时,可有肺气肿体征
D.
湿啰音多在肺底部和背部
E.
喘息型可闻及哮鸣音,而且容易很快完全消失
【单选题】创立卫气营血辨证方法的医家是
A.
叶天士
B.
张仲景
C.
吴鞠通
D.
汪宏
E.
吴又可
【单选题】关于慢性支气管炎体征特点的描述,下列哪项错误
A.
早期可无任何异常体征
B.
急性发作期可有散在千湿罗音
C.
并发肺气肿时,可有肺气肿体征
D.
湿啰音多在肺底部和背部
E.
喘息型可闻及哮鸣音,而且容易很快完全消失
【单选题】关于慢性支气管炎的描述,下列哪项是错误的()。
A.
中年以上男性多见
B.
常反复咳嗽、咳痰
C.
发作性呼气性呼吸困难
D.
可伴喘息症状
E.
可进展为肺心病
【单选题】创立卫气营血辨证方法的医家是
A.
吴鞠通
B.
张元素
C.
朱震亨
D.
李杲
E.
叶天士
【单选题】创立卫气营血辨证方法的医家是()
A.
叶天士
B.
张仲景
C.
吴鞠通
D.
汪昂
E.
吴又可
【单选题】关于慢性支气管炎,下列哪项描述是错误的?
A.
支气管黏膜上皮细胞有不同程度的变性、坏死
B.
支气管壁有大量淋巴细胞、浆细胞浸润
C.
支气管腔内有大量纤维蛋白滞留
D.
黏液腺增生、肥大
E.
黏膜上皮鳞状化生
【单选题】关于慢性支气管炎,下列哪项描述是错误的
A.
支气管粘膜上皮细胞有不同程度的变性、坏死
B.
支气管壁有大量淋巴细胞或中性粒细胞浸润
C.
支气管腔内有大量纤维蛋白潴留
D.
粘液腺增生、肥大
E.
粘膜上皮鳞状上皮化生
【单选题】创立卫气营血辨证方法的医家是:
A.
叶天士
B.
吴鞠通
C.
吴又可
D.
张仲景
【单选题】创立卫气营血辨证方法的医家是
A.
叶天士
B.
张仲景
C.
吴鞠通
D.
汪宏
相关题目:
参考解析:
知识点:
题目纠错 0
发布
创建自己的小题库 - 刷刷题